Modeling amyloid therapy potential on a population level: An adaptation of the MISCAN‐Dementia model

Abstract

Background: Amyloid‐targeting therapies for Alzheimer's disease are currently under consideration or approved for use in various countries. However, the population‐wide impact of these therapies and eligible population remain unclear.